Do you want to read an article? Please log in or register.
Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials
Lung Cancer
Related content
Lung Cancer
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study
Lung Cancer
Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators
doi: 10.1016/j.lungcan.2025.108802
Lung Cancer
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis
Nat Commun
Zhang B, Zhong R, Shi C, Chu T, Zhang W, Wang H, Gan X, Zhang Z, Zhu C, Li X, Su W, Li J, Zhang Y, Han B, Zhong H
doi: 10.1038/s41467-026-73562-7
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
Lung Cancer
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial
Lancet Respir Med
Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS
doi: 10.1016/S2213-2600(26)00192-X
Lung Cancer
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)
Clin Lung Cancer
Mitome N, Hamada A, Wakabayashi M, Uozumi T, Horinouchi H, Isaka M, Yotsukura M, Aokage K, Fukuda H, Watanabe SI, Tsutani Y, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG)
doi: 10.1016/j.cllc.2026.04.006
Lung Cancer
Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial
Lung Cancer
Brosseau S, Etienne H, Peoc'h K, Langlais A, Blanché H, Foucher P, Barlesi F, Domas J, Girard P, Scherpereel A, Dumont P, Derollez M, Quoix E, Debieuvre D, Deleuze JF, Leçon-Malas V, Zalcman G, Westeel V, Mordant P
doi: 10.1016/j.lungcan.2026.109345
RECOMMENDED
Lung Cancer
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Liu Y, Li D, Wu L, Li X, Fan Y, Zhang M, Guo J, Yao Y, Fang J, Tang KJ, Luo F, Yu Y, Min X, Song Z, Hu J, Ma R, Yang H, Shu Y, Xu R, Wang B, Dong X, Chen Y, Mao R, Zhang V, Fang Y
doi: 10.1016/j.cllc.2026.06.003
Lung Cancer
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
Lancet Oncol
Zhang L, Zhang X, Wu L, Xing W, Liu C, Zhang P, Chen K, Shi J, Xu S, Zhang X, Dong X, Fang H, Yu X, Gao Y, Li G, Chen Z, Fan S, Zhang X, Cheng Y
doi: 10.1016/S1470-2045(25)00643-6
Lung Cancer
Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer
Sci Rep
Chen HL, Chueh CH, Huang WM, Chan SH, Cheng HH, Chiang SC, Wu CE, Wen YW, Tsai YW
doi: 10.1038/s41598-025-22966-4